The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures

Michael S. Kraus, James M. Gold, Deanna M. Barch, Trina M. Walker, Charlotte A. Chun, Robert W. Buchanan, John G. Csernansky, Donald C. Goff, Michael F. Green, L. Fredrik Jarskog, Daniel C. Javitt, David Kimhy, Jeffrey A. Lieberman, Joseph P. McEvoy, Raquelle I. Mesholam-Gately, Larry J. Seidman, M. Patricia Ball, Robert S. Kern, Robert P. McMahon, James RobinsonStephen R. Marder, Richard S.E. Keefe

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

In comparison to batteries of standard neuropsychological tests, cognitive neuroscience tests may offer a more specific assessment of discrete neurobiological processes that may be aberrant in schizophrenia. However, more information regarding psychometric properties and correlations with standard neuropsychological tests and functional measures is warranted to establish their validity as treatment outcome measures. The N-back and AX-Continuous Performance Task (AX-CPT) are two promising cognitive neuroscience tests designed to measure specific components of working memory and contextual processing respectively. In the current study, we report the psychometric properties of multiple outcome measures from these two tests as well as their correlations with standard neuropsychological measures and functional capacity measures. The results suggest that while the AX-CPT and N-back display favorable psychometric properties, they do not exhibit greater sensitivity or specificity with functional measures than standard neurocognitive tests.

Original languageEnglish
Article number100161
JournalSchizophrenia Research: Cognition
Volume19
DOIs
StatePublished - Mar 2020
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2019

Funding

This study was funded by National Institute of Mental Health Contract HHSN278200441003C to the University of California, Los Angeles (SRM, Principal Investigator). Double-blind medications were provided by Merck and Company.

FundersFunder number
Merck and Company
National Institute of Mental HealthHHSN278200441003C

    Fingerprint

    Dive into the research topics of 'The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures'. Together they form a unique fingerprint.

    Cite this